JP2022551105A - アバプリチニブでの好酸球性障害の治療 - Google Patents

アバプリチニブでの好酸球性障害の治療 Download PDF

Info

Publication number
JP2022551105A
JP2022551105A JP2022520638A JP2022520638A JP2022551105A JP 2022551105 A JP2022551105 A JP 2022551105A JP 2022520638 A JP2022520638 A JP 2022520638A JP 2022520638 A JP2022520638 A JP 2022520638A JP 2022551105 A JP2022551105 A JP 2022551105A
Authority
JP
Japan
Prior art keywords
eosinophilic
compound
pharmaceutically acceptable
eosinophils
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551105A5 (cg-RX-API-DMAC7.html
Inventor
マー,ブレントン
Original Assignee
ブループリント メディシンズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブループリント メディシンズ コーポレイション filed Critical ブループリント メディシンズ コーポレイション
Publication of JP2022551105A publication Critical patent/JP2022551105A/ja
Publication of JP2022551105A5 publication Critical patent/JP2022551105A5/ja
Priority to JP2025135336A priority Critical patent/JP2025169361A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022520638A 2019-10-04 2020-10-05 アバプリチニブでの好酸球性障害の治療 Pending JP2022551105A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025135336A JP2025169361A (ja) 2019-10-04 2025-08-15 アバプリチニブでの好酸球性障害の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962910931P 2019-10-04 2019-10-04
US62/910,931 2019-10-04
PCT/US2020/054221 WO2021067917A1 (en) 2019-10-04 2020-10-05 Treatment of eosinophilic disorders with avapritinib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025135336A Division JP2025169361A (ja) 2019-10-04 2025-08-15 アバプリチニブでの好酸球性障害の治療

Publications (2)

Publication Number Publication Date
JP2022551105A true JP2022551105A (ja) 2022-12-07
JP2022551105A5 JP2022551105A5 (cg-RX-API-DMAC7.html) 2023-10-13

Family

ID=73030210

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520638A Pending JP2022551105A (ja) 2019-10-04 2020-10-05 アバプリチニブでの好酸球性障害の治療
JP2025135336A Pending JP2025169361A (ja) 2019-10-04 2025-08-15 アバプリチニブでの好酸球性障害の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025135336A Pending JP2025169361A (ja) 2019-10-04 2025-08-15 アバプリチニブでの好酸球性障害の治療

Country Status (6)

Country Link
US (1) US20240075041A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041244B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022551105A (cg-RX-API-DMAC7.html)
CN (1) CN114746096A (cg-RX-API-DMAC7.html)
TW (1) TW202126306A (cg-RX-API-DMAC7.html)
WO (1) WO2021067917A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515978A (ja) * 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー Kit阻害剤に対する獲得耐性を伴う癌の治療
JP2014521624A (ja) * 2011-07-27 2014-08-28 エービー サイエンス 選択的プロテインキナーゼ阻害剤
JP2015520186A (ja) * 2012-06-07 2015-07-16 デシフェラ ファーマシューティカルズ,エルエルシー 増殖性疾患の治療にキナーゼ阻害剤として有用なジヒドロナフチリジン及び関連化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2593319T3 (es) * 2005-05-02 2016-12-07 Novartis Ag Derivados de pirimidilaminobenzamida para síndrome hipereosinofílico
ES2429107T3 (es) * 2007-01-19 2013-11-13 Bayer Healthcare Llc Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT
EP2768480A1 (en) * 2011-10-21 2014-08-27 Rigel Pharmaceuticals, Inc. Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one) -6-yl]-5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine
MX365614B (es) * 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
CN109970745B (zh) * 2018-04-16 2020-12-08 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515978A (ja) * 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー Kit阻害剤に対する獲得耐性を伴う癌の治療
JP2014521624A (ja) * 2011-07-27 2014-08-28 エービー サイエンス 選択的プロテインキナーゼ阻害剤
JP2015520186A (ja) * 2012-06-07 2015-07-16 デシフェラ ファーマシューティカルズ,エルエルシー 増殖性疾患の治療にキナーゼ阻害剤として有用なジヒドロナフチリジン及び関連化合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANNALS OF TRANSLATIONAL MEDICINE, vol. 6(11), JPN7024004255, 2018, pages 232, ISSN: 0005434741 *
BLOOD, vol. 130 (Suppl_1), JPN7024004257, 7 December 2017 (2017-12-07), pages 2, ISSN: 0005434743 *
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, vol. 10, JPN7024004256, 24 September 2015 (2015-09-24), pages 351 - 361, ISSN: 0005434742 *
SCIENCE TRANSLATIONAL MEDICINE, vol. Vol.9, eaao1690, JPN6024040812, 2017, pages 1 - 11, ISSN: 0005572012 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 374, no. 26, JPN6024040811, 2016, pages 2530 - 2541, ISSN: 0005572011 *

Also Published As

Publication number Publication date
EP4041244B1 (en) 2026-07-15
EP4041244A1 (en) 2022-08-17
JP2025169361A (ja) 2025-11-12
TW202126306A (zh) 2021-07-16
WO2021067917A1 (en) 2021-04-08
US20240075041A1 (en) 2024-03-07
CN114746096A (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
EP4385571B1 (en) A lysyl oxidase-like 2 inhibitor for use in treating primary myelofibrosis
JP2017526713A (ja) 線維症を処置するためのセニクリビロック併用療法
US12257237B2 (en) Tinostamustine for use in treating sarcoma
US20200069703A1 (en) Chemical entities that kill senescent cells for use in treating age-related disease
JP2015511632A (ja) メラノーマの治療におけるraf阻害剤およびmek阻害剤の投与
JP2023058635A (ja) 過活動膀胱の治療のためのビベグロンの投薬
US20240000789A1 (en) Therapeutic combinations comprising a craf inhibitor
KR20250099259A (ko) 과민성 방광의 치료를 위한 비베그론의 용도
JP2025106456A (ja) 胆管癌を治療するための方法
JP2025169361A (ja) アバプリチニブでの好酸球性障害の治療
CN117982507A (zh) 英菲格拉替尼在治疗胃癌和腺癌中的用途
JP2023501397A (ja) 肥満細胞疾患および好酸球性障害の治療
CN112533600A (zh) 用于治疗小细胞肺癌的喹啉衍生物
KR20150003786A (ko) Pi3k 저해제 및 mek 저해제를 이용한 암 치료 방법
JP7762224B2 (ja) 線維化症の予防または治療用薬学的組成物
KR20250145693A (ko) 미토겐 활성화 단백질 키나제(mapk) 경로 변경을 이용한 고형 종양의 치료 방법
JP2026516050A (ja) 多発性硬化症を治療するためのbtk阻害剤
CN117295498A (zh) 用于预防或治疗纤维化的药物组合物
HK40096678A (en) Pharmaceutical composition for preventing or treating fibrosis
CN115120596A (zh) 一种喹唑啉化合物及药物组合物的应用
CN115120732A (zh) 一种喹唑啉化合物的药物组合物及其制备方法
HK40046131A (en) Quinoline derivative used for treating small cell lung cancer
JP2022547311A (ja) 骨髄線維症の治療のためのmdm2阻害剤の使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231004

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250410